Carsten Mainitz
The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.
Most recently, he headed a Hamburg-based investment research company as a member of the board for 8 years.
He is particularly interested in international small and micro caps and empirical capital market research (behavioral finance).
Commented by Carsten Mainitz
Commented by Carsten Mainitz on October 28th, 2026 | 05:36 CET
Strategic Resources, thyssenkrupp and Heidelberg Materials: Who Will Benefit Most from the Transformation of Heavy Industry?
Created and Published on Behalf of Power Metallic Mines
Conditions in the construction sector are gradually improving. A few days ago, Heidelberg Materials CEO Dominik von Achten told Reuters of tentative signs of recovery in the third quarter. Investments in energy infrastructure and data centres were slowly progressing. For industry, this is a welcome prospect. New infrastructure needs steel and concrete. At the same time, producers must reduce emissions without losing their competitiveness. This is precisely where the companies converge. Strategic Resources is planning a plant to produce high-quality iron ore pellets needed for lower-emission steel production. With the spin-off of its materials trading and logistics division, thyssenkrupp is taking another decisive step towards becoming a financial holding company. Heidelberg Materials already markets low-carbon cement but is grappling with several challenges. Who will turn these opportunities into rising share prices the fastest?
Commented by Carsten Mainitz on October 28th, 2026 | 05:30 CET
Sow First, Reap Later! Exciting Developments at MustGrow, Bayer and K+S – Who Is Best Positioned?
Created and Published on Behalf of MustGrow Biologics Corp.
Fewer chemicals, healthier soils and higher yields. Agriculture is looking for solutions that combine environmental protection and economic viability. Political support appears to be emerging from Brussels. The EU plans to approve biological crop protection products more quickly and reduce the administrative burden. However, the Council and the European Parliament still need to reach an agreement. At least the direction is right, which could open new opportunities for companies like MustGrow. The Canadians develop mustard-based agricultural products and cooperate with Bayer on biological crop protection through a licensing partnership. The first development milestone payment was made under this partnership in the summer. Bayer's agricultural division focuses on seeds and crop protection. K+S supplies potassium- and magnesium-based fertilisers for agriculture. Ultimately, all three companies face similar challenges: new and existing products must improve yields per hectare while remaining economically viable for farmers. Which stock offers the most value for investors?
Read
Commented by Carsten Mainitz on October 26th, 2026 | 05:29 CET
Share prices are falling, business is growing: What opportunities do Almonty, Rheinmetall and Renk shares offer investors?
The euphoria has apparently faded. Following sharp share price declines, Almonty, Rheinmetall and Renk are increasingly back in focus. With demand trends intact, are these new entry opportunities? After all, without raw materials there is no ammunition; without drive systems there are no mobile armed forces. Almonty has commenced commercial operations at the Sangdong tungsten mine, marking a historic milestone. Rheinmetall and Renk are under scrutiny for how quickly and profitably they can fulfil orders. Wait or buy?
Read
Commented by Carsten Mainitz on October 23rd, 2026 | 05:43 CEST
More Power Requires More Infrastructure! Opportunities for Phenom Resources, Siemens Energy and Nordex?
The energy transition requires grids, power plants, storage systems and raw materials. Electricity must be transported reliably, supplied when needed and stored cost-effectively. This creates opportunities across the entire value chain. Siemens Energy is benefiting from growing demand for energy infrastructure, with its order books full. However, doubts about the AI boom are also mounting. Nordex significantly exceeded expectations with its quarterly results and raised its margin target for the current year. Its shares initially surged before profit-taking set in. Phenom Resources is broadly diversified. The exploration company offers investors exposure to vanadium, gold and other areas. Which share will take off now?
Read
Commented by Carsten Mainitz on October 23rd, 2026 | 05:32 CEST
The Race for Efficiency: HPQ Silicon, BYD and Infineon – Who Will Lead and Who Will Fall Behind?
Created and published on behalf of HPQ Silicon
Electrification requires better batteries and more powerful chips. It also depends on companies that can produce these technologies at competitive costs. HPQ Silicon is approaching this critical juncture. The company aims to increase energy density in battery cells, and its operational progress is gaining momentum. Commercialisation is the next major milestone. Most recently, the Canadian company announced an initiative to establish a US battery company with independent financing. BYD is bringing electric powertrains to the mass market but faces intense competition. Infineon supplies key power electronics components. Could the upcoming results boost the stock? Where are the most compelling opportunities for investors?
Read
Commented by Carsten Mainitz on October 22nd, 2026 | 05:38 CEST
Gold and Concrete Gold: When Asset Values and Share Prices Diverge – Lahontan Gold, Vonovia and LEG Immobilien Under the Microscope
On the stock market, assets sometimes have two prices: a calculated or theoretical value and the current market price, reflected in the share price. When the gap between value and price becomes (too) wide, opportunities may arise for forward-looking investors. Or are these valuation discounts nothing more than a value trap? The latest developments at three companies give us reason to take a closer look. The newly published PEA, which provides an initial indication of the potential value of Lahontan Gold's gold project, values it at eight times (!) the Canadian company's market capitalisation. Real estate stocks have been among the market's laggards in recent months, weighed down by rising interest rates, economic concerns and political uncertainty. Even major players such as Vonovia have been affected. LEG's recent investment highlights how share price declines can create attractive valuation levels. So what does all this mean for investors?
Read
Commented by Carsten Mainitz on October 21st, 2026 | 05:22 CEST
Explosive Mix! Multimillion-Dollar Orders, Lunar Missions and Takeover Buzz Drive Zefiro Methane, OHB and Steyr Motors
Created and published on behalf of Zefiro Methane
An order backlog of around USD 40 million from government-funded projects, studies for European lunar infrastructure and an announced takeover offer. These developments from specialist companies are moving share prices and generating plenty of discussion. Zefiro plugs old wells and has emerged as a hidden champion in the US market, estimated at around USD 500 billion. OHB develops space systems and has an order backlog of more than EUR 3 billion, with new contracts on the horizon. Steyr specialises in diesel engines for military, marine and industrial applications, attracting takeover interest while its share price remains depressed. A prospective acquirer is now offering EUR 39 per share. Which stock will come out on top?
Read
Commented by Carsten Mainitz on October 14th, 2026 | 05:33 CEST
Copper Discoveries, AI Chips and Mobile Communications: Power Metallic, Infineon and Deutsche Telekom After the Pullbacks
Power Metallic Mines, Infineon and Deutsche Telekom come from very different sectors. On the stock market, however, they currently share the same question: do the pullbacks offer buying opportunities? Following its recent resource estimate, Power Metallic is working on an initial economic assessment. Analysts see significant upside potential in the stock. At chipmaker Infineon, expectations for its AI business are rising, and investors are watching for the next results. At the telecommunications group, concerns about new competition from SpaceX are growing. Where are the greatest opportunities?
Read
Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST
Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?
The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?
Read
Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST
Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer
When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?
Read